Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor

Citations Over TimeTop 10% of 2014 papers

Abstract

Genetically modified T cells to recognize tumor-associated antigens by transgenic TCRs or chimeric antigen receptors (CAR) have been successfully applied in clinical trials. However, the disadvantages of either TCR mismatching or the requirement of a surface tumor antigen limit their wider applications in adoptive T cell therapy. A TCR-like chimeric receptor, specific for the melanoma-related gp100/HLA-A2 complex was created by joining a TCR-like antibody GPA7 with the endodomains of CD28 and CD3-ζ chain. This TCR-like CAR, GPA7-28z, was subsequently introduced into human T cells. Retargeted T cells expressing GPA7-28z could exhibit efficient cytotoxic activities against human melanoma cells in vitro in the context with HLA-A2. Furthermore, infusion of GPA7-28z-transduced T cells suppressed melanoma progression in a xenograft mouse model. Redirecting human T cells with TCR-like CARs would be a promising alternative approach to TCR-mediated therapy for melanoma patients, which is also feasible for targeting a variety of other tumor antigens.

Related Papers

• → You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy(2020)109 cited
• → Early and Late Toxicities of Chimeric Antigen Receptor T-Cells(2023)10 cited
• → Chimeric antigen receptor-redirected T cells return to the bench(2016)35 cited
• → [Prospect for chimeric antigen receptor-engineered T cell immunotherapy for solid tumors].(2018)
• → [Advances in Structural Designs of Chimeric Antigen Receptor T Cells--Review].(2022)